2017
DOI: 10.1590/1414-431x20176207
|View full text |Cite
|
Sign up to set email alerts
|

Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells

Abstract: Both sorafenib and interleukin-27 (IL-27) are antineoplastic drugs. This study aimed to investigate the synergistic effect of these two drugs on bladder cancer cells. HTB-9 and T24 cells were stimulated with IL-27 (50 ng/mL), sorafenib (2 μM) or the synergistic action of these two drugs. The cells without treatment acted as control. Cell proliferation, apoptosis and invasion were measured by bromodeoxyuridine assay, flow cytometry and modified Boyden chamber, respectively. Simultaneously, both modified Boyden … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
6
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 35 publications
(37 reference statements)
1
6
0
Order By: Relevance
“…The present study revealed that treating lung cancer cells with cisplatin + IL-27 significantly decreased expression levels of the anti-apoptotic factors Akt and Bcl-2, and augmented expression of the apoptotic factors Bax and caspase-3. This was consistent with our hypothesis and the results obtained in previous studies (31,32).…”
Section: Discussionsupporting
confidence: 94%
See 1 more Smart Citation
“…The present study revealed that treating lung cancer cells with cisplatin + IL-27 significantly decreased expression levels of the anti-apoptotic factors Akt and Bcl-2, and augmented expression of the apoptotic factors Bax and caspase-3. This was consistent with our hypothesis and the results obtained in previous studies (31,32).…”
Section: Discussionsupporting
confidence: 94%
“…A previous study demonstrated that IL-27 could inhibit the proliferation of various cancer cells by suppressing the Akt signaling pathway (30). In a previous study, IL-27 and sorafenib each suppressed bladder cancer cell proliferation, migration and invasion, and increased apoptosis through the AKT/mTOR/mitogen-activated protein kinase pathway (31). It is hypothesized that IL-27 may strengthen the sensitivity of lung cancer cells to drugs by inhibiting the Akt pathway.…”
Section: Discussionmentioning
confidence: 99%
“…For example, because IL-18 has recently been shown to have an unfavorable predictive role in some inflammatory contexts (non-alcoholic fatty liver disease (NAFLD) [48]), for certain therapeutic settings it might be best to utilize 27 or 27pepL single therapies. IL-27 has been reported to augment the anti-tumor effects of sorafenib on bladder cancer cells [49]; thus, there could be promise for utilizing 27-related therapies for this cancer type. One interesting approach could be to engineer IL-27 with a C-terminal peptide mimic of sorafenib as a novel therapy.…”
Section: Discussionmentioning
confidence: 99%
“…Bladder cancer ranks as the 9 th most frequently diagnosed cancer and is 13 th in terms of deaths worldwide since 2012 1. Although accumulating studies show that targeted drugs can improve patient survival rates, first-line molecular-targeted drugs (sorafenib and gefitinib) exhibit only limited therapeutic effects in several clinical trials and can cause severe side effects 2, 3. Therefore, there is an increasing demand to explore effective strategies for bladder urothelial carcinoma (BLCA) treatment.…”
Section: Introductionmentioning
confidence: 99%